Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 5 of 5

Publication Record

Connections

Patterns of prevalent HPV and STI co-infections and associated factors among HIV-negative young Western Cape, South African women: the EVRI trial.
Menezes LJ, Pokharel U, Sudenga SL, Botha MH, Zeier M, Abrahamsen ME, Glashoff RH, Engelbrecht S, Schim van der Loeff MF, van der Laan LE, Kipping S, Taylor D, Giuliano AR
(2018) Sex Transm Infect 94: 55-61
MeSH Terms: Adolescent, Alcohol Drinking, Chlamydia trachomatis, Coinfection, Female, Genotype, Gonorrhea, HIV Infections, HIV Seronegativity, Herpes Genitalis, Herpesvirus 2, Human, Humans, Medically Underserved Area, Papillomaviridae, Papillomavirus Infections, Papillomavirus Vaccines, Prevalence, Sexual Behavior, Sexual Partners, Sexually Transmitted Diseases, South Africa, Syphilis, Young Adult
Show Abstract · Added August 15, 2017
OBJECTIVE - To estimate the prevalence and describe the patterns of concurrent human papillomavirus (HPV) and STIs and associated factors among HIV-negative young Western Cape, South African women participating in the Efficacy of HPV Vaccine to Reduce HIV Infection (EVRI) trial.
METHODS - HIV-negative women aged 16-24 years old were enrolled in the EVRI trial (NCT01489527) and randomised to receive the licensed four-valent HPV vaccine or placebo. At study entry, participants were clinically evaluated for five STIs: herpes simplex virus type 2 (HSV-2), chlamydia, gonorrhoea, syphilis and disease-causing HPV genotypes (6/11/16/18/31/33/35/39/45/51/52/56/58/59/68). Demographic and sexual history characteristics were compared among women with STI co-infections, single infection and no infection using Pearson χ and Mann-Whitney tests. ORs were calculated to evaluate factors associated with STI co-infection prevalence.
RESULTS - Among 388 young women, STI co-infection prevalence was high: 47% had ≥2 concurrent STIs, 36% had a single STI and 17% had none of the five evaluated STIs. HPV/HSV-2 (26%) was the most prevalent co-infection detected followed by HPV/HSV-2/ (CT) (17%) and HPV/CT (15%). Co-infection prevalence was independently associated with alcohol use (adjusted OR=2.01, 95% CI 1.00 to 4.06) and having a sexual partner with an STI (adjusted OR=6.96, 95% CI 1.53 to 30.08).
CONCLUSIONS - Among high-risk young women from underserved communities such as in Southern Africa, a multicomponent prevention strategy that integrates medical and behavioural interventions targeting both men and women is essential to prevent acquisition of concurrent STI infections and consequent disease.
TRIAL REGISTRATION NUMBER - NCT01489527; Post-results.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
0 Communities
1 Members
0 Resources
23 MeSH Terms
Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses.
Jing L, Laing KJ, Dong L, Russell RM, Barlow RS, Haas JG, Ramchandani MS, Johnston C, Buus S, Redwood AJ, White KD, Mallal SA, Phillips EJ, Posavad CM, Wald A, Koelle DM
(2016) J Immunol 196: 2205-2218
MeSH Terms: Alphaherpesvirinae, Antigen Presentation, Antigens, Viral, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Cross Reactions, Cytokines, Epitopes, T-Lymphocyte, Herpesviridae Infections, Herpesvirus 1, Human, Herpesvirus 2, Human, Humans, Peptides, Receptors, Antigen, T-Cell, T-Lymphocyte Subsets, Viral Proteins
Show Abstract · Added March 30, 2020
The Alphaherpesvirinae subfamily includes HSV types 1 and 2 and the sequence-divergent pathogen varicella zoster virus (VZV). T cells, controlled by TCR and HLA molecules that tolerate limited epitope amino acid variation, might cross-react between these microbes. We show that memory PBMC expansion with either HSV or VZV enriches for CD4 T cell lines that recognize the other agent at the whole-virus, protein, and peptide levels, consistent with bidirectional cross-reactivity. HSV-specific CD4 T cells recovered from HSV-seronegative persons can be explained, in part, by such VZV cross-reactivity. HSV-1-reactive CD8 T cells also cross-react with VZV-infected cells, full-length VZV proteins, and VZV peptides, as well as kill VZV-infected dermal fibroblasts. Mono- and cross-reactive CD8 T cells use distinct TCRB CDR3 sequences. Cross-reactivity to VZV is reconstituted by cloning and expressing TCRA/TCRB receptors from T cells that are initially isolated using HSV reagents. Overall, we define 13 novel CD4 and CD8 HSV-VZV cross-reactive epitopes and strongly imply additional cross-reactive peptide sets. Viral proteins can harbor both CD4 and CD8 HSV/VZV cross-reactive epitopes. Quantitative estimates of HSV/VZV cross-reactivity for both CD4 and CD8 T cells vary from 10 to 50%. Based on these findings, we hypothesize that host herpesvirus immune history may influence the pathogenesis and clinical outcome of subsequent infections or vaccinations for related pathogens and that cross-reactive epitopes and TCRs may be useful for multi-alphaherpesvirus vaccine design and adoptive cellular therapy.
Copyright © 2016 by The American Association of Immunologists, Inc.
0 Communities
1 Members
0 Resources
MeSH Terms
Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.
Pavlos R, Mallal S, Ostrov D, Pompeu Y, Phillips E
(2014) J Allergy Clin Immunol Pract 2: 21-33
MeSH Terms: Adult, Anticonvulsants, Carbamazepine, Cytomegalovirus, Dideoxynucleosides, Drug Hypersensitivity Syndrome, Exanthema, Female, Fever, HIV-1, HLA Antigens, Herpesvirus 2, Human, Herpesvirus 3, Human, Humans, Prognosis, Reverse Transcriptase Inhibitors, Risk Factors, Severity of Illness Index, Skin Tests, Stevens-Johnson Syndrome, Virus Activation, Viruses
Show Abstract · Added March 30, 2020
Drug hypersensitivity syndromes such as abacavir hypersensitivity and the severe cutaneous adverse drug reactions have been associated with significant short- and long-term morbidity and mortality. More recently, these immunologically mediated and previously unpredictable diseases have been shown to be associated with primarily class I but also class II HLA alleles. The case of the association of HLA-B*57:01 and abacavir hypersensitivity has created a translational roadmap for how this knowledge can be used in the clinic to prevent severe reactions. Although many hurdles exist to the widespread translation of such HLA screening approaches, our understanding of how drugs interact with the major histocompatibility complex has contributed to the discovery of new models that have provided considerable insights into the immunopathogenesis of severe cutaneous adverse drug reactions and other T-cell-mediated drug hypersensitivity syndromes. Future translation of this knowledge will facilitate the development of preclinical toxicity screening to significantly improve efficacy and safety of drug development and design.
Copyright © 2014 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
0 Communities
1 Members
0 Resources
MeSH Terms
Incidence, prevalence, and epidemiology of herpes simplex virus-2 in HIV-1-positive and HIV-1-negative adolescents.
Sudenga SL, Kempf MC, McGwin G, Wilson CM, Hook EW, Shrestha S
(2012) Sex Transm Dis 39: 300-5
MeSH Terms: Adolescent, CD4 Lymphocyte Count, Female, HIV Seronegativity, HIV Seropositivity, HIV-1, Herpes Genitalis, Herpesvirus 2, Human, Humans, Incidence, Male, Odds Ratio, Prevalence, Risk Factors, Sexual Behavior, Viral Load
Show Abstract · Added August 15, 2017
BACKGROUND - Several studies have assessed risk factors associated with herpes simplex virus-2 (HSV-2) prevalence in adults; however, few have focused on HSV-2 incidence, particularly in adolescents. The objective of this study was to determine HSV-2 prevalence and incidence and associated risk factors in a HIV-1-positive and at risk HIV-1-negative adolescent population.
METHODS - Sera were tested for HSV-2 antibodies in 518 adolescents in the Reaching for Excellence in Adolescent Care and Health cohort at baseline and again at the final follow-up visit. Prevalence at baseline and incidence (per person years) of HSV-2 infection were calculated. Furthermore, among HIV-1-positive individuals, a subgroup analysis was performed to assess risk factors for HSV-2 infection. Conditional logistic regression was used to estimate odds ratios and P values for associations between CD4+ T-cell (CD4+) count, HIV-1 viral load (VL), and HSV-2 acquisition, adjusting for antiretroviral therapy use, other sexually transmitted infections, gender, race, and number of sexual partners.
RESULTS - At baseline, 179 (35%) subjects were HSV-2 positive, with an additional 47 (16%) new cases being identified during a median follow-up time of 1.95 years and an incidence rate of 7.35 cases per 100 person years. Several risk factors were associated with HSV-2 prevalence (being female, non-Hispanic, uncertainty of sexual preference, and HIV-1 positive) and incidence (using drugs, alcohol, and number of new sexual partners). Among HIV-1 positives, an increase in CD4+ count by 50 cell/mm(3) (odds ratio, 1.17; 95% CI, 1.04-1.31, P = 0.008) was associated with HSV-2 acquisition.
CONCLUSIONS - The high prevalence and incidence of HSV-2 infection among adolescents, compared with the general population at this age group suggests a critical need for screening and preventive programs among this targeted group.
0 Communities
1 Members
0 Resources
16 MeSH Terms
An addition to the effect of treating co-infections on HIV-1 viral load.
Modjarrad K, Vermund SH
(2011) Lancet Infect Dis 11: 81
MeSH Terms: Acyclovir, Adolescent, Adult, Antiviral Agents, CD4 Lymphocyte Count, Female, HIV Infections, HIV-1, Herpes Genitalis, Herpesvirus 2, Human, Humans, Middle Aged, Viral Load, Virus Shedding, Young Adult
Added March 5, 2014
0 Communities
1 Members
0 Resources
15 MeSH Terms